 Michael Baratta
Concepts (231)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fear | 17 | 2025 | 362 | 2.380 |
Why?
| | Prefrontal Cortex | 14 | 2025 | 326 | 2.090 |
Why?
| | Stress, Psychological | 18 | 2025 | 1147 | 2.070 |
Why?
| | Dorsal Raphe Nucleus | 7 | 2025 | 31 | 1.370 |
Why?
| | Conditioning, Classical | 5 | 2021 | 120 | 1.340 |
Why?
| | Serotonin | 9 | 2025 | 293 | 1.260 |
Why?
| | Adaptation, Psychological | 3 | 2025 | 705 | 1.100 |
Why?
| | Behavior, Animal | 9 | 2019 | 515 | 1.090 |
Why?
| | Neurons | 11 | 2025 | 1632 | 0.990 |
Why?
| | Rats, Sprague-Dawley | 23 | 2026 | 2522 | 0.910 |
Why?
| | Rats | 26 | 2026 | 5609 | 0.780 |
Why?
| | Behavior Control | 1 | 2022 | 13 | 0.760 |
Why?
| | Stress, Physiological | 4 | 2009 | 455 | 0.690 |
Why?
| | Extinction, Psychological | 5 | 2023 | 92 | 0.690 |
Why?
| | Ketamine | 2 | 2019 | 130 | 0.680 |
Why?
| | Electroshock | 9 | 2019 | 145 | 0.680 |
Why?
| | Glucocorticoids | 1 | 2025 | 539 | 0.670 |
Why?
| | Optogenetics | 6 | 2025 | 108 | 0.670 |
Why?
| | Avoidance Learning | 4 | 2025 | 64 | 0.650 |
Why?
| | Dopamine | 2 | 2022 | 283 | 0.640 |
Why?
| | Resilience, Psychological | 2 | 2018 | 135 | 0.570 |
Why?
| | Animals | 44 | 2026 | 38140 | 0.560 |
Why?
| | Proto-Oncogene Proteins c-fos | 8 | 2025 | 198 | 0.540 |
Why?
| | Exploratory Behavior | 1 | 2018 | 86 | 0.530 |
Why?
| | Ventral Tegmental Area | 4 | 2025 | 60 | 0.510 |
Why?
| | Microglia | 5 | 2021 | 267 | 0.500 |
Why?
| | Neuronal Plasticity | 1 | 2019 | 309 | 0.480 |
Why?
| | Receptor, Serotonin, 5-HT2C | 1 | 2015 | 14 | 0.460 |
Why?
| | Memory Consolidation | 1 | 2015 | 13 | 0.450 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2015 | 61 | 0.450 |
Why?
| | Neuralgia | 3 | 2026 | 144 | 0.430 |
Why?
| | Sex Factors | 2 | 2019 | 2078 | 0.410 |
Why?
| | Fluoxetine | 2 | 2025 | 54 | 0.410 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2019 | 878 | 0.410 |
Why?
| | Interleukin-1beta | 4 | 2025 | 396 | 0.360 |
Why?
| | Glutamic Acid | 2 | 2025 | 252 | 0.360 |
Why?
| | Raphe Nuclei | 3 | 2009 | 110 | 0.350 |
Why?
| | Neural Pathways | 6 | 2026 | 311 | 0.340 |
Why?
| | Helplessness, Learned | 3 | 2025 | 67 | 0.330 |
Why?
| | Somatosensory Cortex | 2 | 2026 | 42 | 0.300 |
Why?
| | Male | 35 | 2026 | 71568 | 0.300 |
Why?
| | Hippocampus | 5 | 2020 | 968 | 0.280 |
Why?
| | Chronic Pain | 2 | 2026 | 283 | 0.260 |
Why?
| | Motor Activity | 2 | 2023 | 722 | 0.250 |
Why?
| | Vesicular Glutamate Transport Protein 2 | 2 | 2025 | 15 | 0.250 |
Why?
| | Somatostatin | 2 | 2025 | 55 | 0.250 |
Why?
| | Physical Conditioning, Animal | 3 | 2024 | 248 | 0.250 |
Why?
| | Social Behavior | 3 | 2025 | 289 | 0.240 |
Why?
| | Psychoneuroimmunology | 1 | 2025 | 10 | 0.230 |
Why?
| | GABAergic Neurons | 1 | 2025 | 34 | 0.220 |
Why?
| | Acute Pain | 1 | 2026 | 54 | 0.220 |
Why?
| | Serotonergic Neurons | 1 | 2025 | 29 | 0.220 |
Why?
| | Parvalbumins | 1 | 2024 | 26 | 0.220 |
Why?
| | Reward | 2 | 2025 | 243 | 0.220 |
Why?
| | Long-Term Potentiation | 2 | 2005 | 198 | 0.210 |
Why?
| | Corticosterone | 1 | 2025 | 244 | 0.210 |
Why?
| | Pituitary-Adrenal System | 1 | 2025 | 168 | 0.210 |
Why?
| | Receptors, Glucocorticoid | 1 | 2025 | 139 | 0.210 |
Why?
| | Dentate Gyrus | 2 | 2005 | 40 | 0.200 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2025 | 201 | 0.200 |
Why?
| | Interneurons | 1 | 2024 | 127 | 0.200 |
Why?
| | Brain | 5 | 2024 | 2901 | 0.200 |
Why?
| | Uncertainty | 2 | 2021 | 140 | 0.190 |
Why?
| | Brain Mapping | 2 | 2018 | 535 | 0.190 |
Why?
| | Neostriatum | 1 | 2022 | 37 | 0.190 |
Why?
| | Receptors, Dopamine D1 | 1 | 2022 | 35 | 0.180 |
Why?
| | Hormones | 1 | 2002 | 136 | 0.180 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2022 | 321 | 0.170 |
Why?
| | Association Learning | 2 | 2015 | 71 | 0.170 |
Why?
| | Microinjections | 3 | 2018 | 93 | 0.170 |
Why?
| | Calcium Signaling | 1 | 2002 | 251 | 0.160 |
Why?
| | Corpus Striatum | 1 | 2022 | 179 | 0.160 |
Why?
| | Amygdala | 3 | 2024 | 199 | 0.160 |
Why?
| | Sex Characteristics | 3 | 2024 | 786 | 0.160 |
Why?
| | Picrotoxin | 2 | 2018 | 12 | 0.160 |
Why?
| | Disease Models, Animal | 3 | 2021 | 4553 | 0.150 |
Why?
| | Learning | 3 | 2025 | 447 | 0.150 |
Why?
| | Hot Temperature | 1 | 2022 | 406 | 0.150 |
Why?
| | Mice, Transgenic | 4 | 2025 | 2182 | 0.140 |
Why?
| | Female | 15 | 2026 | 77569 | 0.140 |
Why?
| | Signal Transduction | 3 | 2025 | 5241 | 0.140 |
Why?
| | Analysis of Variance | 4 | 2010 | 1308 | 0.140 |
Why?
| | Limbic Lobe | 1 | 2018 | 3 | 0.140 |
Why?
| | Neuroanatomical Tract-Tracing Techniques | 1 | 2018 | 5 | 0.140 |
Why?
| | Stilbamidines | 1 | 2018 | 9 | 0.140 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2018 | 107 | 0.130 |
Why?
| | Cognitive Neuroscience | 1 | 2017 | 9 | 0.130 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2020 | 467 | 0.130 |
Why?
| | Mice, Inbred C57BL | 4 | 2025 | 6032 | 0.130 |
Why?
| | Habenula | 1 | 2016 | 13 | 0.130 |
Why?
| | Spinal Cord Dorsal Horn | 1 | 2016 | 5 | 0.120 |
Why?
| | Acoustic Stimulation | 2 | 2008 | 331 | 0.120 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2018 | 232 | 0.120 |
Why?
| | Models, Animal | 1 | 2017 | 394 | 0.120 |
Why?
| | Serotonin 5-HT2 Receptor Antagonists | 1 | 2015 | 10 | 0.120 |
Why?
| | Restraint, Physical | 1 | 2015 | 69 | 0.110 |
Why?
| | Morphine | 1 | 2016 | 167 | 0.110 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2016 | 170 | 0.110 |
Why?
| | Inflammasomes | 1 | 2016 | 147 | 0.110 |
Why?
| | Memory | 1 | 2016 | 296 | 0.110 |
Why?
| | Immunohistochemistry | 5 | 2009 | 1733 | 0.100 |
Why?
| | Mice | 9 | 2025 | 18421 | 0.100 |
Why?
| | Models, Psychological | 1 | 2015 | 299 | 0.100 |
Why?
| | Models, Neurological | 1 | 2015 | 253 | 0.100 |
Why?
| | Cocaine | 1 | 2015 | 161 | 0.100 |
Why?
| | Pyramidal Cells | 1 | 2013 | 79 | 0.100 |
Why?
| | Toll-Like Receptor 4 | 1 | 2015 | 277 | 0.090 |
Why?
| | Anxiety | 4 | 2025 | 1100 | 0.090 |
Why?
| | Neurogenesis | 1 | 2013 | 157 | 0.090 |
Why?
| | Conditioning, Operant | 1 | 2012 | 97 | 0.090 |
Why?
| | Basolateral Nuclear Complex | 2 | 2024 | 11 | 0.090 |
Why?
| | Dopaminergic Neurons | 1 | 2012 | 67 | 0.090 |
Why?
| | Freezing Reaction, Cataleptic | 2 | 2010 | 27 | 0.090 |
Why?
| | Cues | 3 | 2008 | 325 | 0.080 |
Why?
| | Depressive Disorder | 1 | 2013 | 367 | 0.080 |
Why?
| | Muscimol | 2 | 2007 | 23 | 0.080 |
Why?
| | GABA Agonists | 2 | 2007 | 24 | 0.080 |
Why?
| | Escape Reaction | 2 | 2007 | 56 | 0.080 |
Why?
| | Cytokines | 1 | 2018 | 2093 | 0.080 |
Why?
| | Volition | 1 | 2009 | 34 | 0.080 |
Why?
| | Locus Coeruleus | 1 | 2009 | 21 | 0.080 |
Why?
| | Norepinephrine | 1 | 2009 | 193 | 0.070 |
Why?
| | Limbic System | 1 | 2008 | 55 | 0.070 |
Why?
| | Fluorescent Dyes | 1 | 2009 | 327 | 0.070 |
Why?
| | Clozapine | 2 | 2018 | 20 | 0.070 |
Why?
| | Vesicular Inhibitory Amino Acid Transport Proteins | 1 | 2025 | 10 | 0.060 |
Why?
| | Histocompatibility Antigens | 1 | 2006 | 103 | 0.060 |
Why?
| | Behavior | 1 | 2006 | 90 | 0.060 |
Why?
| | Mesencephalon | 1 | 2025 | 64 | 0.060 |
Why?
| | Humans | 10 | 2025 | 143817 | 0.060 |
Why?
| | Hyperalgesia | 1 | 2026 | 131 | 0.050 |
Why?
| | Sucrose | 1 | 2025 | 112 | 0.050 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2009 | 787 | 0.050 |
Why?
| | Interleukins | 1 | 2006 | 252 | 0.050 |
Why?
| | History, 21st Century | 1 | 2025 | 222 | 0.050 |
Why?
| | History, 20th Century | 1 | 2025 | 327 | 0.050 |
Why?
| | Synaptic Transmission | 1 | 2005 | 287 | 0.050 |
Why?
| | Perforant Pathway | 1 | 2002 | 3 | 0.050 |
Why?
| | Ovariectomy | 1 | 2023 | 161 | 0.050 |
Why?
| | Mentors | 1 | 2025 | 214 | 0.050 |
Why?
| | Brain Diseases | 1 | 2004 | 152 | 0.050 |
Why?
| | Alcohol-Related Disorders | 1 | 2004 | 121 | 0.050 |
Why?
| | Mycobacteriaceae | 1 | 2022 | 35 | 0.050 |
Why?
| | Excitatory Postsynaptic Potentials | 1 | 2002 | 117 | 0.050 |
Why?
| | Pathogen-Associated Molecular Pattern Molecules | 1 | 2021 | 7 | 0.050 |
Why?
| | Luteinizing Hormone | 1 | 2002 | 191 | 0.040 |
Why?
| | Nerve Net | 1 | 2024 | 277 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2002 | 1054 | 0.040 |
Why?
| | Follicle Stimulating Hormone | 1 | 2002 | 250 | 0.040 |
Why?
| | Phosphate-Binding Proteins | 1 | 2020 | 6 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2023 | 1270 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 130 | 0.040 |
Why?
| | Progesterone | 1 | 2002 | 255 | 0.040 |
Why?
| | Caspase 1 | 1 | 2020 | 149 | 0.040 |
Why?
| | Peptides | 1 | 2005 | 986 | 0.040 |
Why?
| | Lipopolysaccharides | 2 | 2018 | 873 | 0.040 |
Why?
| | Action Potentials | 1 | 2002 | 508 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 748 | 0.040 |
Why?
| | Estradiol | 1 | 2002 | 538 | 0.040 |
Why?
| | Optical Fibers | 1 | 2018 | 17 | 0.030 |
Why?
| | Designer Drugs | 1 | 2018 | 6 | 0.030 |
Why?
| | RNA, Messenger | 3 | 2015 | 2847 | 0.030 |
Why?
| | Physical Exertion | 1 | 2019 | 211 | 0.030 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2002 | 424 | 0.030 |
Why?
| | Immunoassay | 1 | 2018 | 112 | 0.030 |
Why?
| | Microdialysis | 2 | 2008 | 54 | 0.030 |
Why?
| | Calcium | 1 | 2002 | 1181 | 0.030 |
Why?
| | Rats, Long-Evans | 1 | 2016 | 127 | 0.030 |
Why?
| | Antibodies | 1 | 2018 | 399 | 0.030 |
Why?
| | Rats, Inbred F344 | 1 | 2016 | 269 | 0.030 |
Why?
| | Random Allocation | 1 | 2016 | 364 | 0.030 |
Why?
| | Transfection | 1 | 2018 | 952 | 0.030 |
Why?
| | Spinal Cord | 1 | 2018 | 381 | 0.030 |
Why?
| | Alcoholism | 1 | 2002 | 814 | 0.030 |
Why?
| | Gene Expression Regulation | 3 | 2010 | 2620 | 0.030 |
Why?
| | Mice, Inbred C3H | 1 | 2015 | 251 | 0.030 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2015 | 59 | 0.030 |
Why?
| | Self Administration | 1 | 2015 | 125 | 0.030 |
Why?
| | Neuroglia | 1 | 2015 | 173 | 0.030 |
Why?
| | Naloxone | 1 | 2015 | 132 | 0.030 |
Why?
| | Electrophysiological Phenomena | 1 | 2013 | 60 | 0.020 |
Why?
| | Substance-Related Disorders | 1 | 2002 | 1079 | 0.020 |
Why?
| | Narcotic Antagonists | 1 | 2015 | 205 | 0.020 |
Why?
| | Channelrhodopsins | 1 | 2012 | 19 | 0.020 |
Why?
| | Rotation | 1 | 2012 | 119 | 0.020 |
Why?
| | Exercise | 1 | 2024 | 2196 | 0.020 |
Why?
| | Locomotion | 1 | 2012 | 103 | 0.020 |
Why?
| | Photic Stimulation | 1 | 2012 | 262 | 0.020 |
Why?
| | GABA Antagonists | 1 | 2010 | 34 | 0.020 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2009 | 71 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2009 | 320 | 0.020 |
Why?
| | Electric Stimulation | 1 | 2009 | 278 | 0.020 |
Why?
| | Software | 1 | 2013 | 690 | 0.020 |
Why?
| | Chronic Disease | 1 | 2013 | 1826 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2015 | 4172 | 0.020 |
Why?
| | Time Factors | 2 | 2010 | 7068 | 0.020 |
Why?
| | Safety | 1 | 2008 | 352 | 0.020 |
Why?
| | Inflammation | 1 | 2018 | 2893 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 863 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2013 | 2540 | 0.010 |
Why?
| | Afferent Pathways | 1 | 2005 | 46 | 0.010 |
Why?
| | Apoptosis | 1 | 2013 | 2446 | 0.010 |
Why?
| | Cell Count | 1 | 2005 | 324 | 0.010 |
Why?
| | Memory Disorders | 1 | 2005 | 195 | 0.010 |
Why?
| | Evoked Potentials, Visual | 1 | 2004 | 41 | 0.010 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 382 | 0.010 |
Why?
| | Mutation | 1 | 2015 | 4106 | 0.010 |
Why?
| | Reaction Time | 1 | 2005 | 441 | 0.010 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2005 | 591 | 0.010 |
Why?
| | Frontal Lobe | 1 | 2004 | 159 | 0.010 |
Why?
| | Pituitary Gland, Anterior | 1 | 2002 | 38 | 0.010 |
Why?
| | Receptors, LHRH | 1 | 2002 | 14 | 0.010 |
Why?
| | Hypothalamus | 1 | 2002 | 156 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2005 | 1255 | 0.010 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2002 | 212 | 0.010 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2005 | 904 | 0.010 |
Why?
| | Ethanol | 1 | 2004 | 626 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2006 | 1817 | 0.010 |
Why?
| | Oxygen | 1 | 2004 | 1000 | 0.010 |
Why?
| | Macrophages | 1 | 2006 | 1508 | 0.010 |
Why?
| | Psychometrics | 1 | 2002 | 728 | 0.010 |
Why?
| | Pilot Projects | 1 | 2004 | 1851 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2002 | 2030 | 0.010 |
Why?
| | Neuropsychological Tests | 1 | 2002 | 1122 | 0.010 |
Why?
| | Comorbidity | 1 | 2002 | 1638 | 0.010 |
Why?
| | Aging | 1 | 2005 | 1968 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2002 | 3392 | 0.010 |
Why?
| | Adolescent | 2 | 2004 | 22233 | 0.010 |
Why?
| | Risk Assessment | 1 | 2002 | 3556 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2004 | 3834 | 0.010 |
Why?
| | Adult | 2 | 2004 | 40128 | 0.000 |
Why?
|
|
Baratta's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|